BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Genzyme  Europe  B.V.  submitted  on  2  September  2002  an  application  for  Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
Cholestagel, through the centralised procedure. After agreement by the CPMP  on 21 February 2002, 
this  medicinal  product  has  been  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EEC) 
2309/93 of 22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr Frits Lekkerkerker  
Co-Rapporteur:  Dr Lars Gramstad  
Scientific Advice: 
The applicant did not seek scientific advice at the CPMP. 
Licensing status: 
Colesevelam has been given a Marketing Authorisation in USA on 26 May 2000 under the invented 
name WelChol. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 23 September 2002. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on 
3 December 2002.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP 
members on 3 December 2002. 
During  the  meeting  on  21  –  23  January  2003,  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 23 January 2003. 
The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 
13 May 2003. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CPMP members on 23 June 2003. 
During  the  CPMP  meeting  on  22  –  24  July  2003,  the  CPMP  agreed  on  a  List  of  Outstanding 
Issues to be addressed in writing and, if necessary, in an oral explanation by the applicant. The 
List of Outstanding Issues was sent to the applicant on 24 July 2003. 
The  applicant  submitted  written  responses  to  the  CPMP  List  of  Outstanding  Issues  on  8 
September 2003. 
The  Rapporteurs  circulated  the  Joint  Review  on  the  applicant’s  responses  to  the  List  of 
Outstanding Issues to all CPMP members on 1 October 2003. 
During the CPMP meeting on 21-22 October 2003, it was decided that in the light of the written 
responses provided there was no need for the applicant to address outstanding issues during an 
oral hearing before the CPMP. 
During the CPMP meeting on 21 – 22 October 2003, the CPMP agreed on a List of Outstanding 
Issues to be addressed in writing by the applicant. The List of Outstanding Issues was sent to the 
applicant on 23 October 2003.  
The  applicant  submitted  written  responses  to  the  CPMP  List  of  Outstanding  Issues  on  31 
October 2003. 
The  Rapporteurs  circulated  the  Joint  Review  on  the  applicant’s  responses  to  the  List  of 
Outstanding Issues to all CPMP members on 10 November 2003. 
1/2 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
During  the  meeting  on  18  -  20  November  2003,  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting  a  Marketing  Authorisation  to  Cholestagel  on  20  November  2003.  The  applicant 
provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation 
on 18 November 2003.  
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 10 March 2004. 
2/2 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
